CN115916771A - 多靶点的抗肿瘤化合物及其制备方法和应用 - Google Patents

多靶点的抗肿瘤化合物及其制备方法和应用 Download PDF

Info

Publication number
CN115916771A
CN115916771A CN202180022963.XA CN202180022963A CN115916771A CN 115916771 A CN115916771 A CN 115916771A CN 202180022963 A CN202180022963 A CN 202180022963A CN 115916771 A CN115916771 A CN 115916771A
Authority
CN
China
Prior art keywords
amino
pyran
tetrahydro
benzamide
indazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180022963.XA
Other languages
English (en)
Inventor
许忻
陈嘉
王贯
杨旭芹
李强
张雨云
陈春桥
张小娟
瞿敏凯
周晓波
王艺瑾
王影
夏小二
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhejiang Huahai Pharmaceutical Co Ltd
Shanghai Synergy Pharmaceutical Sciences Co Ltd
Original Assignee
Zhejiang Huahai Pharmaceutical Co Ltd
Shanghai Synergy Pharmaceutical Sciences Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhejiang Huahai Pharmaceutical Co Ltd, Shanghai Synergy Pharmaceutical Sciences Co Ltd filed Critical Zhejiang Huahai Pharmaceutical Co Ltd
Publication of CN115916771A publication Critical patent/CN115916771A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

一类新的具有多重激酶抑制活性的小分子化合物，其具有通式II所示的结构，通式II所示的化合物在预防或治疗肺癌、淋巴癌等多种癌症适应症中具有良好的药效和安全性。

Description

PCT国内申请，说明书已公开。

Claims (11)

  1. PCT国内申请，权利要求书已公开。
CN202180022963.XA 2020-04-02 2021-04-02 多靶点的抗肿瘤化合物及其制备方法和应用 Pending CN115916771A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2020102526695 2020-04-02
CN202010252669 2020-04-02
PCT/CN2021/085239 WO2021197467A1 (zh) 2020-04-02 2021-04-02 多靶点的抗肿瘤化合物及其制备方法和应用

Publications (1)

Publication Number Publication Date
CN115916771A true CN115916771A (zh) 2023-04-04

Family

ID=77927801

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180022963.XA Pending CN115916771A (zh) 2020-04-02 2021-04-02 多靶点的抗肿瘤化合物及其制备方法和应用

Country Status (2)

Country Link
CN (1) CN115916771A (zh)
WO (1) WO2021197467A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114685371A (zh) * 2022-03-08 2022-07-01 四川大学 吡唑甲酰胺衍生物及其制备方法和用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2693901C (en) * 2007-07-20 2015-12-29 Nerviano Medical Sciences S.R.L. Substituted indazole derivatives active as kinase inhibitors
FR2970967B1 (fr) * 2011-01-27 2013-02-15 Pf Medicament Derives de type azaindazole ou diazaindazole comme medicament
WO2015143652A1 (en) * 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF
US10336707B2 (en) * 2014-12-16 2019-07-02 Eudendron S.R.L. Heterocyclic derivatives modulating activity of certain protein kinases
EP3626709A1 (en) * 2017-06-26 2020-03-25 Shenzhen Targetrx, Inc. Indazole compound for use in inhibiting kinase activity, composition and application thereof

Also Published As

Publication number Publication date
WO2021197467A1 (zh) 2021-10-07

Similar Documents

Publication Publication Date Title
CN113651814B (zh) Kras突变蛋白抑制剂
CN110627796B (zh) 含氮杂环类衍生物及其在医药上的应用
CN113637005A (zh) 用于癌症治疗的kras抑制剂
AU2020446002A1 (en) Benzothiazolyl biaryl compound, and preparation method and use
KR101828187B1 (ko) 신규 축합 피리미딘 화합물 또는 그 염
KR102051609B1 (ko) 2-아릴아미노피리딘, 피리미딘 또는 트리아진 유도체 및 그 제조방법과 사용
WO2021115457A9 (zh) 吡唑并[1,5-a]吡啶类化合物及其制备方法和应用
CN112538072A (zh) 新型氨基嘧啶类egfr抑制剂
CN110267959B (zh) 作为PI3Kδ抑制剂的咪唑并[1,5-A]吡嗪衍生物
CN110520416B (zh) 多取代吡啶酮类衍生物、其制备方法及其医药用途
CN114423758A (zh) 抗细菌化合物
CN112979655A (zh) 三唑并哒嗪类衍生物、其制备方法、药物组合物和用途
CN115515949A (zh) 新型氨基嘧啶类egfr抑制剂
JP2023538091A (ja) Ｂｔｋ阻害剤としての複素環式化合物
KR20230002721A (ko) Egfr 억제제로서의 삼환계 화합물
WO2023179600A1 (zh) 新型取代大杂环类新化合物及其应用
WO2023071998A1 (zh) 新型嘧啶或三嗪取代吡啶并杂环化合物
WO2020207476A1 (zh) 一种吡唑并吡嗪衍生的化合物、药物组合物以及其用途
CN115916771A (zh) 多靶点的抗肿瘤化合物及其制备方法和应用
CN114075200A (zh) 用于治疗重症肺炎的jak抑制剂化合物
CN112047939A (zh) 一种具有抗肿瘤活性的四氢吡啶并嘧啶类化合物
CN113366008A (zh) 一种cd73抑制剂，其制备方法和应用
TW202346297A (zh) 具有抗ｋｒａｓ突變腫瘤活性的化合物
CN115353512A (zh) 一种杂环脲类化合物及其制备方法和用途
CN115073426A (zh) 嘧啶杂环化合物及其制备方法和应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination